敗血症の定義に関する重要文献集 Dｒ.Marshallの論文もあります

 敗血症の定義に関する重要文献集 

1. Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee (1992) Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20:864–874

2. Marshall JC (2000) SIRS and MODS: what is their relevance to the science and practice of intensive care? Shock 14:586–589

3. Vincent J-L (1997) Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med 25:372–374

4. Ramsay G, Gerlach H, Levy MM, et al (2003) An international sepsis survey: a study of doctors' knowledge and perception about sepsis. Crit Care Med 2003

5. Joint International Society and Federation of Cardiology/World Health Organization Task Force on Standardization of Clinical Nomenclature (1979) Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 59:607–609

6. Falahati A, Sharkey SW, Christensen D, et al (1999) Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction. Am Heart J 137:332–337

7. Antman EM, Grudzien C, Mitchell RN, et al (2002) Detection of unsuspected myocardial necrosis by rapid bedside assay for cardiac troponin T. Am Heart J 133:596–598

8. Puleo PR, Meyer D, Wathen C, et al (2002) Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out acute myocardial infarction. N Engl J Med 331:561–566

9. Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction (2000) Myocardial infarction redefined–-a consensus document. J Am Coll Cardiol 36:959–969

10. Taniguchi T, Koido Y, Aiboshi J, et al (1999) Change in the ratio of interleukin-6 to interleukin-10 predicts a poor outcome in patients with systemic inflammatory response syndrome. Crit Care Med 27:1262–1264

11. Ueda S, Nishio K, Minamino N, et al (1999) Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 160:132–136

12. Stoiser B, Knapp S, Thalhammer F, et al (1998) Time course of immunological markers in patients with the systemic inflammatory response syndrome: evaluation of sCD14, sVCAM-1, sELAM-1, MIP-1 alpha and TGF-beta 2. Eur J Clin Invest 28:672–678

13. Hietaranta A, Kemppainen E, Puolakkainen P, et al (2002) Extracellular phospholipases A2 in relation to systemic inflammatory response syndrome (SIRS) and systemic complications in severe acute pancreatitis. Pancreas 18:385–391

14. Takala A, Jousela I, Olkkola KT, et al (1999) Systemic inflammatory response syndrome without systemic inflammation in acutely ill patients admitted to hospital in a medical emergency. Clin Sci (Colch) 96:287–295

15. Sablotzki A, Borgermann J, Baulig W, Friedrich I, Spillner J, Silber RE, Czeslick E (2001) Lipopolysaccharide-binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery. Thorac Cardiovasc Surg 49:273–8]

16. Harbarth S, Holeckova K, Froidevaux C, et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396–340

17. Duflo F, Debon R, Monneret G, et al (2002) Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 96:74–79

18. Angus DC, Linde-Zwirble WT, Lidicer J, et al (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303–1310

19. Marshall JC, Cook DJ, Christou NV, et al (1995) Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 23:1638–1652

20. Ferreira FL, Bota DP, Bross A, et al (2002) Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 286:1754–1758

21. Wilkinson JD, Pollack MM, Ruttiman, et al (1986) Outcome of pediatric patient with multiple organ system failure Crit Care Med 14:271–274

22. Proulx F, Fagan M, Farrell CA, et al (1996) Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest 109:1033–1037

23. Doughty LA, Carcillo JA, Kaplan, et al (1996) Plasma nitrite and nitrate concentration and multiple organ failure in pediatric sepsis Crit Care Med 109:1033–1037

24. Leteutre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F LaCroix J, LeClerc Fl (1999) Pediatric logistic dysfunction score. Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Makingaking 19:399-410

25. Carcillo JA, Fields AI (2002) Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 30:1365–1378

26. Denoix PX (1946) Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1:70–75

27. Gospodarowicz M, Benedet L, Hutter RV, et al (1998) History and international developments in cancer staging. Cancer Prev Control 2:262–268

28. Renaud B, Brun-Buisson C, ICU-Bacteremia Study Group (2001) Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 163:1584–1590

29. Opal SM, Cohen J (1999) Clinical gram-positive sepsis: does it fundamentally differ from gram-negative bacterial sepsis? Crit Care Med 27:1608–1616

30. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al (1991) Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin: a randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436

31. Wortel CH, von der Mohlen MAM, van Deventer SJH, et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 166:1367–1374

32. McCloskey RV, Straube RC, Sanders C, et al (1994) Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 121:1–5

33. Hausfater P, Garric S, Ayed SB, et al (2002) Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 34:895–901

34. Damas P, Ledoux D, Nys M, et al (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356–362

35. Panacek EA, Kaul M (1999) IL-6 as a marker of excessive TNF-alpha activity in sepsis. Sepsis 3:65–73

36. Bernard GR, Vincent J-L, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709

37. Annane D, Sébille V, Charpentier C, et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871

38. Vincent J-L, Moreno R, Takala J, et al on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (1996) The SOFA (Sepsis-Related Organ Failure Assessment) score to describe organ dysfunction/failure. Intensive Care Med 22:707–710

39. Marshall JC, Panacek EA, Teoh L, et al (2001) Modeling organ dysfunction as a risk factor, outcome, and measure of biologic effect in sepsis. Crit Care Med 28:A46

40. Eli Lilly and Company (2001) Briefing document for XIGRIS for the treatment of severe sepsis. http:www.fda.gov/ohrms/dockets/ac/01/briefing/3797b1_01_Sponsor.htm, 6 August

41. Cook R, Cook DJ, Tilley J, et al for the Canadian Critical Care Trials Group (2001) Multiple organ dysfunction: baseline and serial component scores. Crit Care Med 29:2046–2050